2 results
Approved WMORecruiting
To compare OS between gilteritinib and midostaurin in combination with induction therapy and consolidation therapy followed by one-year maintenance therapy in patients with newly diagnosed AML with a FLT3 gene mutation eligible for intensive…
Approved WMOCompleted
To assess whether HBOT reduces pain, and improves physical functioning and QoL in breast cancer patients with late radiation toxicity.